Last reviewed · How we verify
hMG-HP
At a glance
| Generic name | hMG-HP |
|---|---|
| Also known as | Meriofert |
| Sponsor | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin
- Retrospective Study of High Dose Follitropin Delta in a Mixed Protocol With Human Chorionic Gonadotropin
- Menopur And Rekovelle Combination Study Version 2.0 (PHASE2)
- Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial (PHASE3)
- Second Phase of the Pilot Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women (NA)
- Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer
- Type of Gonadotropin and Embryo Kinetics of Development (PHASE4)
- MEDAM (Menopur Retrospective Data prograM)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hMG-HP CI brief — competitive landscape report
- hMG-HP updates RSS · CI watch RSS
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau portfolio CI